Evidence map›Paper›PMID 41772317›Full record

ReviewJournal of neurovirology2026

NeuroViOme: a viral orfeome collection for studies of neurodegenerative disease.

Benjamin Weller, Chung-Wen Lin, Simin Rothballer, Michael A Calderwood, Pascal Falter-Braun, Claudia Falter

Abstract readReview
In one paragraph

Review in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Benjamin WellerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center, Helmholtz Center Munich, German Research Center for Environmental Health, Munich- Neuherberg, Germany. benjamin.weller@helmholtz-munich.de.
Chung-Wen LinInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center, Helmholtz Center Munich, German Research Center for Environmental Health, Munich- Neuherberg, Germany.
Simin RothballerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center, Helmholtz Center Munich, German Research Center for Environmental Health, Munich- Neuherberg, Germany.
Michael A CalderwoodCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, US.
Pascal Falter-BraunInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center, Helmholtz Center Munich, German Research Center for Environmental Health, Munich- Neuherberg, Germany.
Claudia FalterInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center, Helmholtz Center Munich, German Research Center for Environmental Health, Munich- Neuherberg, Germany. claudia.falter@helmholtz-munich.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases such as Alzheimer's and Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS) pose a global health challenge due to their progressive course and lack of curative therapies. These conditions lead to severe neurological decline, significantly impacting patient independence and quality of life, and ultimately result in lethal outcome. Emerging evidence suggests that viral infections contribute to the onset and progression of these neurological diseases, Leblanc and Vorberg (PLoS Pathog 18:e1010670, 2022), either by directly inducing neurological symptoms or by triggering immune responses resulting in neuropathology. Nevertheless, systematic studies of the direct interplay between viral and host proteins in neurodegeneration remain scarce. A key aspect of viral pathogenesis is direct interaction between viral and host proteins (protein-protein interactions, PPIs), which are essential for viral replication and can disrupt or redirect host cell function Kim et al. (Nat Biotechnol, 2022); Zhou et al. (Res Sq, 2022), potentially contributing to the development of diseases traditionally considered non-communicable. Understanding these molecular mechanisms is crucial for advancing diagnostic and therapeutic strategies in neurodegenerative conditions, particularly ALS and MS. To enable systematic studies of these interactions, we introduce NeuroViOme as ORFeome resource encompassing nearly all protein-coding sequences from nine viruses selected based on their prevalence, neurotropism, and mechanistic or epidemiological links to neurodegenerative processes. NeuroViOme includes ORFs from Enteroviruses (EV-A71, EV-D68, CVB3, Echovirus E30), Herpesviruses (HSV-1, EBV, HHV3/Varicella Zoster), the endogenous retrovirus HERV-K, and Polyomavirus JCPyV. To our knowledge, this represents the most comprehensive viral ORF set assembled for neurodegeneration research to date. The collection builds the foundation for interactome mapping and functional genomics analyses and provides a valuable basis for systematic studies of viral perturbations of host pathways.

Indexed as

Neurodegenerative DiseasesAmyotrophic Lateral SclerosisAnimalsGenome, ViralHerpesvirus 4, HumanHost-Pathogen InteractionsHumansJC VirusAmyotrophic lateral sclerosisNeurodegenerative diseasesNeurotrophic virusORFeomeViral pathogenesis

Identifiers

PMID41772317
PMCPMC12953343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.